Literature DB >> 2944367

Spectrum of cardiac involvement in Friedreich's ataxia: clinical, electrocardiographic and echocardiographic observations.

E T Alboliras, C Shub, M R Gomez, W D Edwards, D J Hagler, G S Reeder, J B Seward, A J Tajik.   

Abstract

Combined 2-dimensional and M-mode echocardiography was used to assess the cardiac status of 22 patients with Friedreich's ataxia, and the findings were correlated with the clinical and electrocardiographic (ECG) data. Mean age at onset of Friedreich's ataxia was 8 years (range 3 to 18); mean age at echocardiography was 18 years (range 8 to 39). Echocardiographic findings were abnormal in 19 patients (86%). The 3 patients with normal echocardiographic findings did not have cardiac symptoms, but 1 had ECG repolarization abnormalities. Concentric left ventricular (LV) thickening, the most common echocardiographic finding, was found in 15 patients (68%) and in all 15 the papillary muscles were thickened. These 15 patients had ECG repolarization abnormalities and 5 had left-axis deviation; however, only 3 satisfied ECG criteria for LV or right ventricular hypertrophy. Two of the 15 patients (9%) had symptoms of heart failure. Two patients had asymmetric septal thickening without clinical evidence of LV outflow tract obstruction; neither had cardiac symptoms, but both had ECG repolarization abnormalities. Two patients showed a dilated cardiomyopathy pattern; both had heart failure and atrial flutter. One of these patients died, and necropsy revealed 4-chamber cardiac dilatation, biventricular hypertrophy and histologic findings of diffuse interstitial fibrosis, myocellular hypertrophy and necrosis. This study revealed a wide spectrum of cardiac abnormalities in patients with Friedreich's ataxia.

Entities:  

Mesh:

Year:  1986        PMID: 2944367     DOI: 10.1016/0002-9149(86)90026-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  17 in total

1.  Secondary and Infiltrative Cardiomyopathies.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-10

Review 2.  Friedreich's ataxia: pathology, pathogenesis, and molecular genetics.

Authors:  Arnulf H Koeppen
Journal:  J Neurol Sci       Date:  2011-04-15       Impact factor: 3.181

Review 3.  Friedreich's Ataxia: a review from a cardiology perspective.

Authors:  T Bourke; D Keane
Journal:  Ir J Med Sci       Date:  2011-08-07       Impact factor: 1.568

4.  Cardiomyopathy of Friedreich's ataxia: use of mouse models to understand human disease and guide therapeutic development.

Authors:  R Mark Payne; P Melanie Pride; Clifford M Babbey
Journal:  Pediatr Cardiol       Date:  2011-03-01       Impact factor: 1.655

5.  Large left ventricular thrombus in a patient with Friedreich's ataxia.

Authors:  K Reynen; D Claus; A Bornemann
Journal:  Heart       Date:  1996-01       Impact factor: 5.994

6.  Anaesthesia for a patient with Friedreich's ataxia and cardiomyopathy.

Authors:  A M Campbell; G A Finley
Journal:  Can J Anaesth       Date:  1989-01       Impact factor: 5.063

7.  A family segregating a Friedreich ataxia phenotype that is not linked to the FRDA locus.

Authors:  P Smeyers; E Monrós; J Vílchez; J Lopez-Arlandis; F Prieto; F Palau
Journal:  Hum Genet       Date:  1996-06       Impact factor: 4.132

8.  The clinical spectrum of Friedreich's ataxia in German families showing linkage to the FRDA locus on chromosome 9.

Authors:  W Müller-Felber; T Rossmanith; C Spes; S Chamberlain; D Pongratz; T Deufel
Journal:  Clin Investig       Date:  1993-02

9.  Friedreich ataxia (FA) associated with diabetes mellitus type 1 and hyperthrophic cardiomyopathy.

Authors:  Zoran Gucev; Velibor Tasic; Aleksandra Jancevska; Nada Popjordanova; Svetlana Koceva; Marija Kuturec; Vesna Sabolic
Journal:  Bosn J Basic Med Sci       Date:  2009-05       Impact factor: 3.363

10.  Marked variation in the cardiomyopathy associated with Friedreich's ataxia.

Authors:  D P Dutka; J E Donnelly; P Nihoyannopoulos; C M Oakley; D J Nunez
Journal:  Heart       Date:  1999-02       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.